|
|
| Ligne 1 : |
Ligne 1 : |
| <br>By Ludwig Burger and Yadarisa Shabong<br> <br>Aug 16 (Reuters) - GlaxoSmithKline and CureVac said a study website on macaque monkeys showed their jointly-developed mRNA COVID-19 vaccine candidate to be "strongly improved" in protecting against the virus compared with CureVac's first attempt.<br> <br>The encouraging news on its "second-generation" vaccine gave CureVac's German-listed shares an 8% lift, as the stock gradually recovers from a slump in June when the German biotech company's first vaccine candidate recorded a disappointing 48% efficacy in mass testing on humans.<br> <br>The companies said on Monday that a blood analysis of the animals showed that the next-generation vaccine known as CV2CoV triggered virus-fighting antibodies as well as immune cells that target infected cells faster and in greater quantities than CureVac's first-generation vaccine candidate.<br> <br>The surge in antibodies and immune cells was similar to that observed after a real infection with SARS-CoV-2, [https://Www.Localpines.com/united-states/new-orleans/marketing-programs-20-services/one-click-seo digital marketing agency course] the coronavirus that causes COVID-19, they said.<br> <br>Higher antibody blood counts were observed across virus variants of concern, including the Beta, Delta and Lambda lineages, they added.<br> <br>When infected with the original SARS-CoV-2 virus detected in the Chinese city of Wuhan, macaques vaccinated with CV2CoV had better [https://ajt-ventures.com/?s=clearance clearance] of the virus in the lungs and nasal passages, when comparing the two vaccines.<br> <br>The results have yet to be peer-reviewed for publication in a medical journal.<br> <br>U.S.-listed shares of CureVac, which also reported its quarterly financial results on Monday, were up 9.5% in pre-market trading.<br> <br>GSK and CureVac teamed up in February in a 150 million euro ($177 million) deal to develop the next-generation COVID-19 vaccine from next year, in an attempt to tackle several variants with one shot.<br> <br>Initial testing of CV2CoV on humans would begin during the last [https://www.Wikipedia.org/wiki/quarter quarter] of this year, CureVac said.<br><br>($1 = 0.8496 euros) (Reporting by Yadarisa Shabong in Bengaluru; Editing by Maju Samuel and Barbara Lewis)<br><br>adverts.addToArray("pos":"inread_player")Advertisement
| | |
Version actuelle datée du 7 mars 2024 à 20:20
Historique du fichier
Cliquer sur une date et heure pour voir le fichier tel qu'il était à ce moment-là.
| Date et heure | Vignette | Dimensions | Utilisateur | Commentaire |
|---|
| actuel | 7 mars 2024 à 20:20 |  | 775 × 673 (134 Kio) | Yves.lenoc (discussion | contributions) | |
Vous ne pouvez pas remplacer ce fichier.
Utilisation du fichier
La page suivante utilise ce fichier :
